Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007;34(3):143-5.

Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss

S Dendrinos  1 , I Kalogirou, E Makrakis, T Theodoridis, E A Mahmound, V Christopoulou-Cokkinou, G Creatsas
Affiliations
  • PMID: 17937086
Randomized Controlled Trial

Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss

S Dendrinos et al. Clin Exp Obstet Gynecol. 2007.

Abstract

Purpose: To assess the safety and efficacy of tinzaparin sodium for the management of recurrent pregnancy loss.

Methods: The study included 62 women with a history of recurrent pregnancy loss and at least one factor of thrombophilic disorder. Of these, 31 received 50 IU/kg of tinzaparin sodium daily (Group A), and 33 received 100 mg of aspirin daily (Group B).

Results: Group A subjects (receiving tinzaparin sodium) had six new abortions, whereas Group B subjects (receiving aspirin) had 11 (significant difference). Cases of intrauterine growth restriction (none in Group A and 2 in Group B), placental abruption (one in Group A and 4 in Group B), and preeclampsia (one in Group A and 3 in Group B) were comparable between the two groups. Finally coagulation disorders (none in Group A and 6 in Group B) were significantly fewer in Group A.

Conclusion: A 50 IU/kg daily dose of tinzaparin sodium seems to be effective for the management of recurrent abortion and has high standards of safety.

PubMed Disclaimer

Publication types